This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Claudio Albano, MD; Leonardo Cocito, MD
Neurology Clinic University of Genoa Via de Toni, 5 16132 Genoa, Italy

Arch Neurol. 1979;36(5):322.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We read with interest the letter from Frattola et al (35:60, 1978) about the mechanisms of action of bromocriptine in Huntington's chorea. According to the authors, bromocriptine should be considered as a partial dopaminergic agonist, with a "biphasic effect" that depends on the dosage.

Similar effects have been observed by us after the administration of bromocriptine to 11 patients affected by Huntington's chorea¹: involuntary movements showed a good improvement when the daily dosage of bromocriptine was low (< 40 mg/day), whereas a slight worsening was seen after the administration of higher dosages (40 to 60 mg/day). Moreover, CSF HVA levels substantially increased after the low-dosage treatment with bromocriptine, and substantially decreased when a high dosage was used.

These data, namely, the increase in CSF HVA levels associated with the clinical improvement of choreic movements, suggest that dopamine-sensitive receptors in the neostriatum are blocked, from a low . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?